Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | +55.10% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | +55.10% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a positive outlook on their ongoing projects. However, they did not provide specific guidance for future performance.
Management highlighted progress in their pipeline despite not providing specific revenue guidance.
They emphasized their commitment to advancing their therapies.
Ionis Pharmaceuticals reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising by 1.92%. The company did not disclose revenue figures or future guidance, leaving investors with limited insights into its financial trajectory. The stock's increase suggests that investors are encouraged by the EPS beat and the management's focus on pipeline development.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Hawaiian Electric Industries, Inc.